Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Abstract Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yannan Zhao, Cheng Liu, Yingjian Zhang, Chengcheng Gong, Yi Li, Yizhao Xie, Bingrui Wu, Zhongyi Yang, Biyun Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Metastatic Breast Cancer Patients Total Lesion Glycolysis (TLG) Intra-tumor Heterogeneity Heterogeneity Parameter Metabolic Tumor Volume Medicine R Science Q
Acceso en línea:	https://doaj.org/article/53499fd6cb6449139ee0ba36d9607cf7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53499fd6cb6449139ee0ba36d9607cf7
record_format	dspace
spelling	oai:doaj.org-article:53499fd6cb6449139ee0ba36d9607cf72021-12-02T15:09:02ZPrognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study10.1038/s41598-018-32745-z2045-2322https://doaj.org/article/53499fd6cb6449139ee0ba36d9607cf72018-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-32745-zhttps://doaj.org/toc/2045-2322Abstract Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)-positive/HER2-negative metastatic breast cancer patients who received 500 mg fulvestrant and underwent 18F-FDG PET/CT before treatment were retrospectively included. In PET/CT scans, conventional parameters (maximum and mean standardized uptake value, metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and heterogeneity parameters (intra-tumor heterogeneity index [HI] and inter-tumor heterogeneity coefficient of variation [COV]) were analyzed. Progression-free survival (PFS) was mainly assessed for efficacy. The survival analyses were performed using the Kaplan–Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard model. Univariate analysis indicated that a high SUVmax and a high tumor HI at baseline were associated with longer PFS of fulvestrant (P = 0.036 and P = 0.033, respectively). Liver metastasis, SUVmax and HI were statistically significant in multivariate analysis (P values of 0.017, 0.025 and 0.043, respectively). 18F-FDG based intra-tumor heterogeneity appears to be a potential predicator of efficacy of fulvestrant among HR+HER2− metastatic breast cancer patients.Yannan ZhaoCheng LiuYingjian ZhangChengcheng GongYi LiYizhao XieBingrui WuZhongyi YangBiyun WangNature PortfolioarticleMetastatic Breast Cancer PatientsTotal Lesion Glycolysis (TLG)Intra-tumor HeterogeneityHeterogeneity ParameterMetabolic Tumor VolumeMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-7 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Metastatic Breast Cancer Patients Total Lesion Glycolysis (TLG) Intra-tumor Heterogeneity Heterogeneity Parameter Metabolic Tumor Volume Medicine R Science Q
spellingShingle	Metastatic Breast Cancer Patients Total Lesion Glycolysis (TLG) Intra-tumor Heterogeneity Heterogeneity Parameter Metabolic Tumor Volume Medicine R Science Q Yannan Zhao Cheng Liu Yingjian Zhang Chengcheng Gong Yi Li Yizhao Xie Bingrui Wu Zhongyi Yang Biyun Wang Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
description	Abstract Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)-positive/HER2-negative metastatic breast cancer patients who received 500 mg fulvestrant and underwent 18F-FDG PET/CT before treatment were retrospectively included. In PET/CT scans, conventional parameters (maximum and mean standardized uptake value, metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and heterogeneity parameters (intra-tumor heterogeneity index [HI] and inter-tumor heterogeneity coefficient of variation [COV]) were analyzed. Progression-free survival (PFS) was mainly assessed for efficacy. The survival analyses were performed using the Kaplan–Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard model. Univariate analysis indicated that a high SUVmax and a high tumor HI at baseline were associated with longer PFS of fulvestrant (P = 0.036 and P = 0.033, respectively). Liver metastasis, SUVmax and HI were statistically significant in multivariate analysis (P values of 0.017, 0.025 and 0.043, respectively). 18F-FDG based intra-tumor heterogeneity appears to be a potential predicator of efficacy of fulvestrant among HR+HER2− metastatic breast cancer patients.
format	article
author	Yannan Zhao Cheng Liu Yingjian Zhang Chengcheng Gong Yi Li Yizhao Xie Bingrui Wu Zhongyi Yang Biyun Wang
author_facet	Yannan Zhao Cheng Liu Yingjian Zhang Chengcheng Gong Yi Li Yizhao Xie Bingrui Wu Zhongyi Yang Biyun Wang
author_sort	Yannan Zhao
title	Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
title_short	Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
title_full	Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
title_fullStr	Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
title_full_unstemmed	Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
title_sort	prognostic value of tumor heterogeneity on 18f-fdg pet/ct in hr+her2− metastatic breast cancer patients receiving 500 mg fulvestrant: a retrospective study
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/53499fd6cb6449139ee0ba36d9607cf7
work_keys_str_mv	AT yannanzhao prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT chengliu prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT yingjianzhang prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT chengchenggong prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT yili prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT yizhaoxie prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT bingruiwu prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT zhongyiyang prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy AT biyunwang prognosticvalueoftumorheterogeneityon18ffdgpetctinhrher2metastaticbreastcancerpatientsreceiving500mgfulvestrantaretrospectivestudy
_version_	1718387936946290688

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Ejemplares similares